Dolutegravir/lamivudine

Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains dolutegravir, as the salt, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI). It is taken by mouth.

It was approved for use in the United States in April 2019, and in the European Union in July 2019, and again with revisions in June 2022.

The most common side effects are headache, diarrhea, nausea, and difficulty sleeping. The most common serious side effects are allergic reactions, including rash and severe liver problems.

Dolutegravir/lamivudine is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.